The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xu, Shaohua ^a   Wang, Tao ^b   Song, Wen ^b   Jiang, Tao ^c   Zhang, Feng ^d   Yin, Yu ^e   Jiang, Shi Wen ^f   Wu, Kongming ^b   Yu, Zuoren ^g   Wang, Chenguang ^h   Chen, Ke ^b  

^a Shanghai First Maternity and Infant Health Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Department of General Surgery QingZhou People Hospital   (China)

^d THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e ANHUI MEDICAL UNIVERSITY   (China)

^f MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Tongji University   (China)

^h INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; ANDROGEN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; MICRORNA; MIRN190 MICRORNA, HUMAN; PROTEIN BINDING; Y BOX BINDING PROTEIN 1; YBX1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; CELL PROLIFERATION; DRUG EFFECTS; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANDROGENS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; Y-BOX-BINDING PROTEIN 1;

EID: 84940568356     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13528     Document Type: Article

References (38)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013).
2. So, A. et al. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23, 1-9 (2005).
3. Sung, Y. Y. & Cheung, E. Androgen receptor co-regulatory networks in castration-resistant prostate cancer. Endocr Relat Cancer 21, R1-R11 (2013).
4. Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr Rev 25, 276-308 (2004).
5. Devlin, H. L. & Mudryj, M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274, 177-86 (2009).
6. Coppola, V., De, Maria. R. & Bonci, D. MicroRNAs and prostate cancer. Endocr Relat Cancer 17, F1-17 (2010).
7. Maugeri-Sacca, M. et al. MicroRNAs and prostate cancer: From preclinical research to translational oncology. Cancer J 18, 253-261 (2012).
8. Almog, N. et al. Transcriptional changes induced by the tumor dormancy-associated microRNA 190. Transcription 4, 177-191 (2013).
9. Chu, H. W. et al. A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. Hum Mol Genet 23, 355-67 (2014).
10. Shiota, M. et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer 18, 505-17 (2011).
11. Shahriar, Koochekpour. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12, 639-657 (2010).
12. Li, H. et al. Identification of novel androgen receptor antagonists using structure- and ligand-based methods. J Chem Inf Model 53, 123-30 (2013).
13. Culig, Z. et al. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92, 265-271 (2004).
14. Stan, S. D. & Singh, S. V. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res 15, 4895-4903 (2009).
15. Snoek, R. et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15, 39-47 (2009).
16. Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93, 233-41 (2004)
17. Agoulnik, I. U. & Weigel, N. L. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99, 362-372 (2006).
18. Chmelar, R. et al. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120, 719-733 (2007).
19. Singh, P. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13, 653-666 (2006).
20. Hagman, Z. et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108, 1668-76 (2013).
21. Qu, F. et al. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem 377, 121-30 (2013).
22. Shi, X. B. et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 32, 4130-8 (2013).
23. Sun, D. et al. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene 33, 1448-57 (2014).
24. Tao, Wang. et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget 5, 3611-21 (2014).
25. Lyabin, D. N., Eliseeva, I. A. & Ovchinnikov, L. P. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA 5, 95-110 (2014).
26. Eliseeva, I. A. et al. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 76, 1402-33 (2011).
27. Zhu, X. et al. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai) 45, 80-6 (2013).
28. Felgueiras, J., Silva, J. V. & Fardilha, M. Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B 15, 16-42 (2014).
29. Imada, K. et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancerprogression. Clin Cancer Res 19, 4638-50 (2013).
30. Shiota, M. et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 187, 707-14 (2012).
31. Tao, Wang. et al. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget 5, 10293-10306 (2014).
32. Kato, M. et al. Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem 285, 34004-15 (2010).
33. Armengol, G., Ruiz, L. M. & Orduz, S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol Biotechnol 27, 109-18 (2004).
34. Giorno, F. et al. Developmental and heat stress-regulated expression of HsfA2 and small heat shock proteins in tomato anthers. J Exp Bot 61, 453-62 (2010).
35. Redshaw, N. et al. A comparison of miRNA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. Biotechniques 54, 155-64 (2013).
36. Wu, K. et al. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res 74, 829-39 (2014).
37. Zhang, Y. et al. Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real Time PCR Analysis. World J Surg 33, 698-709 (2009).
38. Ma, Y. et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun 3, 1291 (2013).